Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835596 | 0.92 | DRD2 (0.45) | THRBDRD2HTR7TP53MAPT | |
| SCHEMBL6835231 | 0.91 | MAPT (0.47) | THRBDRD2HTR7TP53POLB | |
| SCHEMBL6831716 | 0.91 | MAPT (0.42) | THRBDRD2HTR7TP53MAPT | |
| SCHEMBL6837107 | 0.90 | RXFP1 (0.48) | DRD2POLBMAPTROCK2SMN1; SMN2 | |
| SCHEMBL6834726 | 0.90 | EPHX2 (0.43) | THRBDRD2TP53MAPTSMN1; SMN2 | |
| SCHEMBL6831861 | 0.90 | HTR7 (0.47) | THRBDRD2HTR7TP53MAPT | |
| SCHEMBL6831784 | 0.89 | PPARG (0.42) | THRBDRD2HTR7TP53MAPT | |
| SCHEMBL6834741 | 0.85 | ALDH1A1 (0.47) | DRD2TP53POLBMAPTROCK2 | |
| SCHEMBL6669286 | 0.85 | ALDH1A1 (0.54) | DRD2ALDH1A1 | |
| SCHEMBL6835323 | 0.83 | RXRA (0.39) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | claimed |
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | THRB 3648/4885DRD2 1883/4885HTR7 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.